ArticleFrontiers in physiology2026
Decoding isonicotinylation-associated patterns in neutrophil chronic obstructive pulmonary disease: evidence from integrative bioinformatic-driven multi-omics and
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is driven by complex inflammatory processes in which neutrophil dysregulation plays a central role. Isonicotinylation (Kinic), a novel lysine acylation modification linked to cellular metabolism, has not yet been clearly associated with COPD. Methods: We employed an artificial intelligence (AI)-driven, multi-omics framework. First, the Limma, WGCNA, and CIBERSORT algorithms were used to identify a Kinic- and neutrophil (KN)-associated shared molecular signature in the peripheral blood bulk profiles of COPD patients. Next, NMF and explainable machine learning identified molecular subgroups and developed a diagnostic model for COPD patients based on the KN-associated gene signature. In addition, a KN-associated pathogenic hub factor was identified, and its molecular and immune signatures in COPD were assessed using a cutting-edge analytical framework in spatial and temporal manners. An AI-based drug screening platform (DrugReflector) and molecular docking were used to identify therapeutic candidates. Finally, Lymphotoxin-beta (LTB) expression was validated Results: We identified a robust five-gene KN-associated signature that demonstrated diagnostic and patient-stratification potential in COPD. LTB was identified as an upregulated Kinic-associated hub gene mainly distributed in neutrophils and involved in the regulation of COPD pathogenesis. Notably, BRD-K97481123 was identified as a potential LTB-targeting compound for the treatment of COPD. Conclusion: This study unveils a novel KN-associated molecular axis in COPD pathogenesis, with LTB as a neutrophil-centric pathogenic factor. This axis provides a framework for patient stratification, offers a promising diagnostic biomarker, and identifies a potential therapeutic target, thereby linking a novel metabolic modification to neutrophilic inflammation in COPD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.